Results from the AVEIR DR i2i Investigational Device Exemption (IDE) study through three-months post-implant showed a 98.3% implant success rate for physicians and more than 97% of people had a successful atrio-ventricular synchrony, so that the upper and lower chamber were beating normally, despite different types of underlying slow heart rhythms.
New data presented at the Technology and Heart Failure Therapeutics (THT) Conference showed that hemodynamic monitoring can slow the progression of heart failure in patients with reduced ejection fraction.
Physicians are looking for better ways to treat patients with congestive heart failure. This includes the integration of remote monitoring and novel technologies.
During a session at this week’s Consumer Electronics Show, Andrea Wainer, EVP of Rapid Molecular Diagnostics at Abbott, shares how the company scaled up to supply the global market with more than 300 million COVID-19 tests in 2020 and the path forward.
AdvaMed’s Diagnostic Supply Registry is tracking the progress of molecular diagnostic tests to help support state and federal governments.
The FreeStyle Libre 2 now has indications for children ages four and older.
The Abbott ID NOW test may return false negative results.
Diagnostic companies are hustling to increase availability of testing.
The G4 gives doctors an additional range of clip sizes, along with enabling real-time procedure assessment.
The device can be implanted in babies weighing as little as two pounds.